Exchange: NASDAQ·Updated 07:58 PM EST
AZN logo

AZN AstraZeneca PLC

$174.35
$1.06
(0.60%)
Today
Closed $174.35
$0.52
(0.30%)
After Hours
Reported EarningsOct 30
Mkt Cap$270.4B
Vol2.02M

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.
55

Bullish Sentiment

How do you feel about AZN?

topstockalerts
AstraZeneca is considering entering the cancer vaccine market, exploring one of oncology’s most active research areas as pharmaceutical companies investigate new ways to prevent tumors from returning and treat different forms of cancer. CEO Pascal Soriot told analysts at the European Society for Medical Oncology conference in Madrid that cancer vaccines have been the subject of extensive internal discussions. Soriot said AstraZeneca’s research and development team has made significant progress in mRNA technology over the past several years, giving the company confidence that it could develop meaningful opportunities in the field. He added that further details could emerge over the coming months and years. The British drugmaker has previous vaccine experience through its COVID-19 vaccine developed with Oxford University, although its core focus remains cancer treatments, cardiometabolic diseases and rare conditions. $AZN
1
2
jmig
$AZN listened to most of the call this morning while on the road. Company loaded not only with a stacked pipeline of drugs but with leadership with vision and strong execution skills. Would not be surprised with this hitting 250 plus in 2027.
4
Theflash88
$AZN $AZN should focus on other GLP-1 drugs now that $RYTM is unlikely to happen. $GPCR or $VKTX make more sense. I own all of them including RYTM.
3
RockyTSTH
$AZN $RYTM 'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Conditions And Severe Obesity' - WSJ Exclusive
3
defion
$AZN Good things to come! Firing on all cylinders and the sales, pipeline, helping patients, and overal exec gameplan is looking good. Keep up the momentum
3
sawyer3d6614
Completely different size than $AZN, but $GOAI gives me concrete research points - ads, AI marketing, and a new crypto platform
2
PennyScam
$AZN For deeper thinkers. I wonder if we will be in the new government portfolio now that we know what Larry’s plans are here. You know what I’m talking about. Ck
2
defion
$AZN thinking about going long here 3k shares been eyeing it up for a while now. Read the call transcript, reviewed their pipeline, and other tidbits. A large commit on my side, so looking at community thoughts now. What’s your take on going long?
2
cmgventure
$AZN | ASTRAZENECA PLC Q3 2026 EARNINGS HIGHLIGHTS ◆ EPS: $2.79 vs. $2.60 est. ✅ ◆ Revenue: $16.21B vs. $16.00B est. ✅ ◆ Operating Income: $4.39B (+22.0% YoY) ◆ Core Operating Income: $5.86B (+17.0% YoY) ◆ R&D Expense: $3.89B (+6.0% YoY) ◆ SG&A Expense: $5.11B (+0.0% YoY) Key Metrics: ◆ Core Operating Margin expanded 4pp at CER to 36% in Q3 2026, driven by positive product mix and operating leverage. ◆ Reported Operating Margin was 27%, up 3pp year-on-year, with reported operating profit up 22%. ◆ AstraZeneca invested $2.0BN in Summit Therapeutics in October, acquiring roughly 12% of outstanding common stock. Forward Guidance: ◆ FY 2026 Total Revenue expected to increase by a mid-to-high single-digit percentage at CER. ◆ FY 2026 Core EPS expected to increase by a low double-digit percentage at CER. ◆ FY 2026 Core Tax rate expected to be between 18-22%. ◆ FX tailwind: if October-December 2026 rates hold at September 2026 averages, Total Revenue benefits from a low single-digit percentage positive impact vs. CER.
2
GweiGamma
$AZN sitting at an interesting spot here. Pipeline news keeps trickling in but market seems hesitant to price it in yet. Risk/reward looks decent if you believe in the catalysts, but patience is clearly required. Not a name for the impatient crowd right now.
1
NicholasABrown
$AZN - (Bloomberg) - AstraZeneca Plc cut about 600 jobs from its respiratory and immunology commercial teams in the US, an early indication of how it plans to reallocate resources to further grow its pipeline of new drugs. https://www.bloomberg.com/news/articles/2026-11-13/astrazeneca-cuts-600-us-sales-staff-as-savings-drive-kicks-in?srnd=homepage-americas
1
Quantum_Capital_LLC
$AZN chart is starting to bubble up. Strong bounce off the 155 support, could see new 52 weeks high.
1
StocktwitsNews
AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat $AZN https://stocktwits.com/news/equity/markets/astra-zeneca-ceo-sees-over-20b-potential-from-2027-drug-trial-readouts-azn-stock-eyes-breakout/cZUhAwOR9Th
1
AlertsAndNews
$AZN multiple headline here this weekend. Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 TAGRISSO plus savolitinib extended median overall survival by nearly five months TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO "Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)."
1
PennyScam
$AZN Thanks for the update Lilly. That’s a real mouthful. Looks great to me. Any thoughts on combinations, mergers and acquisitions? I love all the possibilities here. I’m a BMS, ASTRA ( Big Momma ) fan. Eventually Marc will get things done. I don’t know much about the other characters you mentioned. I’m sure they are all fun but Big Momma is the one that rocks my world. She’s amazing in so many great ways. For now, Soriot is making all the right choices. My opinion is that Astra is still laying out pipe with BMS. Something is still happening. I feel it. Just my opinion based on my DD. Lilly, do you know of Marc de Garidel? He’s my Waldo here. Marc is a brilliant wrangler. Best in the business. I believe I can beat him at pickleball, but that’s another story. Same goes for you Teper. 😉😊 Thanks for helping us out Lilly of the Valley. 👍🏻 You stay you and keep informing us on all the latest news. Keep believing Lilly. You will be greatly rewarded. Ck
Bobear12
$AZN @ could MDGL troubling news start to create interest in GALT? What are the chances for fast track approval from the FDA?
Bobear12
$AZN thought you should know. Galectin Therapeutics Inc. (GALT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy).
topstockalerts
AstraZeneca is eliminating approximately 600 jobs in its U.S. respiratory and immunology commercial operations as part of a broader strategy to redirect spending toward its drug development pipeline, according to Bloomberg. The cuts affect employees marketing its asthma treatments Breztri and Airsupra, although some may be reassigned to other departments. The reductions are part of a three-year restructuring program expected to generate $1.5 billion in annual pretax savings, while incurring up to $2 billion in charges. CEO Pascal Soriot plans to reinvest much of the savings in R&D, particularly oncology, rare diseases and other priority areas, while shifting resources away from mature drugs facing patent expirations, including Farxiga and Brilinta. The respiratory and immunology division generated approximately 14% of AstraZeneca’s revenue last year, growing 12%, but faces competitive and pricing pressures from treatments such as GSK’s Trelegy and Sanofi/Regeneron’s Dupixent. $AZN
topstockalerts
AstraZeneca reportedly submitted a $10B acquisition offer for Rhythm Pharmaceuticals, proposing $124 per share last month, according to The Wall Street Journal. Rhythm shares surged to close at $110.68, compared with approximately $95 earlier in the session, increasing the company's market capitalization to roughly $7.7B from $6.6B before the rally. The closing price remained below AstraZeneca's reported offer, suggesting investors were factoring in the possibility of a transaction while retaining some uncertainty over its completion. The potential acquisition would significantly expand AstraZeneca's rare-disease portfolio and strengthen its presence in treatments for rare metabolic disorders, particularly severe obesity. Rhythm specializes in therapies targeting genetic conditions associated with appetite regulation and metabolic dysfunction, offering AstraZeneca an opportunity to broaden its exposure to specialized obesity treatments beyond conventional weight-loss drugs. $AZN $RYTM

Advertisement|Remove ads.